|
Dr. Jonathan H. Dinsmore serves as Senior VP Regulatory and Clinical of the company and was formally responsible for all aspects of Mytogen’s cell production operations, basic science program, and research and development efforts. He was also actively engaged in evaluating partnership opportunities and complimentary technologies. Prior to his position with Advanced Cell Technology and Mytogen, he directed both clinical and preclinical research programs at Diacrin and GenVec. He has research and clinical experience in the development of therapeutic products to treat Parkinson’s disease, Huntington’s disease, epilepsy, stroke, spinal cord injury, chronic intractable pain, liver disease, and cardiovascular disease. Dr. Dinsmore received a B.S. in Biology from Boston College in 1983 followed by a Ph.D. in Biology from Dartmouth College in 1988. He then trained four years as a Post-doctoral Fellow at Massachusetts Institute of Technology, after which he joined Diacrin in 1992. His extensive accomplishments include numerous awarded and pending patents as well as diverse published studies on myoblast transplantation technology. | 